ELEVEN BIOTHERAPEUTICS INC 
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 15.62M 21.32M | Sales 2025 * | 12.96M 17.69M | Capitalization | 61.48M 83.93M |
|---|---|---|---|---|---|
| Net income 2024 * | -57M -77.81M | Net income 2025 * | -68M -92.82M | EV / Sales 2024 * | 3.94 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.74 x |
| P/E ratio 2024 * |
-1.17
x | P/E ratio 2025 * |
-1.14
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
Sesen Bio, Inc. is a late-stage clinical company engaged in advancing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company's advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
Sector
-
Calendar
Related indices